Systematic approach to study alternative splicing from scRNA-seq in cancer

Bidragets beskrivning

Alternative splicing has been shown to play important roles in cancer development. Currently, most alternative splicing studies stay on bulk RNA-seq level. Although it is estimated that 92% of human genes undergo alternative splicing, studies using bulk RNA-seq can only uncover alternative splicing for a small proportion of genes in cancer. This is due to the heterogeneous nature of cancer, in which significant splicing events specific for a cell population are averaged out over all heterogenous cells. Therefore, it is natural to resort to single cell RNA sequencing (scRNA-seq) to handle the heterogeneity in cancer. In this project, I will use a multi-omics approach to systematically study alternative splicing and its regulation from scRNA-seq of cancer.
Visa mer

Startår

2020

Slutår

2025

Beviljade finansiering

Lu Cheng Orcid -palvelun logo
321 864 €

Andra beslut

358086
Akademiforskarens forskningskostnader(2023)
31 215 €
365453
Akademiforskare(2024)
117 033 €
365524
Akademiforskarens forskningskostnader(2023)
168 564 €
335858
Akademiforskarens forskningskostnader(2020)
299 931 €

Finansiär

Finlands Akademi

Typ av finansiering

Akademiforskare

Övriga uppgifter

Finansieringsbeslutets nummer

330407

Vetenskapsområden

Biomedicinska vetenskaper

Forskningsområden

Systeemibiologia, bioinformatiikka

Identifierade teman

cancer